ABT-751
- Generic Name
- ABT-751
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H17N3O4S
- CAS Number
- 141430-65-1
- Unique Ingredient Identifier
- WDT5V5OB9F
- Background
ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00471718
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2021-03-17
- Target Recruit Count
- 9
- Registration Number
- NCT00439296
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 92
- Registration Number
- NCT00436852
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Abbott
- Target Recruit Count
- 75
- Registration Number
- NCT00354562
- Locations
- 🇺🇸
Site Ref # / Investigator 3571, Nashville, Tennessee, United States
🇮🇪Site Ref # / Investigator 5097, Cork, Ireland
🇨🇦Site Ref # / Investigator 3563, Sydney, Nova Scotia, Canada
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 165
- Registration Number
- NCT00297089
- Locations
- 🇺🇸
Site Reference ID/Investigator# 3353, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 6006, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 2411, Fort Lauderdale, Florida, United States
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-11-18
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 30
- Registration Number
- NCT00073151
- Locations
- 🇺🇸
Dayton Oncology and Hematology, Kettering, Ohio, United States
🇺🇸Oncology Hematology Group of South Florida, Miami, Florida, United States
🇺🇸Oncology & Hematology Associates of Kansas City, PA, Kansas City, Missouri, United States
A Study of ABT-751 in Patients With Colorectal Cancer
- Conditions
- First Posted Date
- 2003-11-18
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00073138
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Wisconsin Medical Center, Madison, Wisconsin, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of ABT-751 in Patients With Renal Cell Cancer
- Conditions
- First Posted Date
- 2003-11-18
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 60
- Registration Number
- NCT00073112
- Locations
- 🇺🇸
US Oncology Inc Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇨🇦B.C. Vancouver Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦McGill University, Montreal, Quebec, Canada
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
- Conditions
- First Posted Date
- 2003-06-23
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00063102
- Locations
- 🇺🇸
Oncology-Hematology Group of South Florida, Miami, Florida, United States
🇺🇸Clinical Research Network, Inc., Plantation, Florida, United States
🇺🇸Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion, Indianapolis, Indiana, United States
ABT-751 in Treating Young Patients With Refractory Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 90
- Registration Number
- NCT00036959
- Locations
- 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.